Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer

MLA

Alan Nichol, et al. “Impact of TAILORx on Chemotherapy Prescribing and 21-Gene Recurrence Score-Guided Treatment Costs in a Population-Based Cohort of Patients with Breast Cancer.” CancerReferences, vol. 128, no. 4, Sept. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5174bd060aab510921637f93658eb37b&authtype=sso&custid=ns315887.

APA

Alan Nichol, Caroline Speers, Stuart Peacock, Megan E. Tesch, Rekha M. Diocee, Caroline Lohrisch, & Lovedeep Gondara. (2021). Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer. CancerReferences, 128(4).

Chicago

Alan Nichol, Caroline Speers, Stuart Peacock, Megan E. Tesch, Rekha M. Diocee, Caroline Lohrisch, and Lovedeep Gondara. 2021. “Impact of TAILORx on Chemotherapy Prescribing and 21-Gene Recurrence Score-Guided Treatment Costs in a Population-Based Cohort of Patients with Breast Cancer.” CancerReferences 128 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5174bd060aab510921637f93658eb37b&authtype=sso&custid=ns315887.